Strategic Global Market Access: The Role of Health-Technology Assessments in Navigating Access Barriers for Biopharmaceuticals
Bio-process Intl • Wed Jan 29 2025
Global advancements in the development of biologics and advanced-therapy medicinal products (ATMPs) are transforming the world of medicine through the approval of novel breakthrough therapies that treat previously uncurable diseases. However, many barriers stand between therapies and widespread access.
Global advancements in the development of biologics and advanced-therapy medicinal products (ATMPs) are transforming the world of medicine through the approval of novel breakthrough therapies that treat previously uncurable diseases. However, many barriers stand between therapies and widespread access. Some of the most prominent hurdles are high treatment costs, which pose a significant obstacle for patients and other stakeholders, including employers, government-funded healthcare programs, commercial payers, healthcare providers, and drug manufacturers. Shared goals across the industry include improved affordability and accessibility to address health inequities and quality of life (QoL) for patients worldwide.
Click here to read more about the role of health technology assessments
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.